Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 9,649 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Human Clear all
Withdrawn No phase listed Observational

B-Cell Hematologic Malignancy Vaccination Registry

NCT02298816
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Waldenstrom Macroglobulinemia, Lymphocytosis, Lymphoma, Non-Hodgkin, B-Cell Chronic Lymphocytic Leukemia, Hematological Malignancies
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 25, 2026, 7:23 PM EDT
Completed No phase listed Observational

Natural Matrix Protein™ (NMP™) in Interbody Lumbar Fusion

NCT05972616
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Natural Matrix Protein (NMP)
Biological
Lead sponsor
Induce Biologics USA Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 25, 2026, 7:23 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

NCT02661464
View directory record Official record
Conditions
Hemorrhagic Fever, Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
0 Years to 71 Years
Enrollment
677 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 25, 2026, 7:23 PM EDT
Completed Not applicable Interventional

Recovery of Bladder and Sexual Function After Human Spinal Cord Injury

NCT04193709
View directory record Official record
Conditions
Urinary Bladder, Neurogenic, Blood Pressure, Autonomic Dysreflexia, Bowel Incontinence
Interventions
Spinal Cord Epidural Stimulation
Device
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 25, 2026, 7:23 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

NCT05655221
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
B1344, Placebo
Drug · Other
Lead sponsor
Tasly Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 25, 2026, 7:23 PM EDT
Completed Phase 1 Interventional

Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease

NCT05031806
View directory record Official record
Conditions
Dry Eye Disease
Interventions
iNexin™ (0.08% aCT1), iNexin™ (0.4% aCT1), iNexin™ (2.0% aCT1), Vehicle (eye drop formulation without aCT1)
Drug
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 25, 2026, 7:23 PM EDT
Terminated Phase 1 Interventional Results available

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

NCT03260504
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma
Interventions
Aldesleukin, Pembrolizumab
Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 25, 2026, 7:23 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cytokine Response to Abdominal Wall Reconstruction

NCT07422584
View directory record Official record
Conditions
Incisional Ventral Hernia
Interventions
Not applicable- observational study
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 25, 2026, 7:23 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans

NCT03201952
View directory record Official record
Conditions
Glucose Intolerance, Gastric Bypass Surgery
Interventions
Ursodeoxycholic Acid, Placebos
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 25, 2026, 7:23 PM EDT
Completed Not applicable Interventional Results available

Combining Objective and Subjective Sedation Assessment Tools

NCT00734409
View directory record Official record
Conditions
Critical Illness
Interventions
Bispectral Index (BIS) Monitor
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 25, 2026, 7:23 PM EDT
Terminated Phase 2 Interventional Results available

Trastuzumab and Vinorelbine in Advanced Breast Cancer

NCT01185509
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
trastuzumab, vinorelbine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 25, 2026, 7:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

NCT05631093
View directory record Official record
Conditions
HIV-1 Infection
Interventions
ART, DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Palm Springs, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 25, 2026, 7:23 PM EDT
Not listed Phase 2 Interventional

Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

NCT01730716
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Human spinal cord stem cell implantation
Device
Lead sponsor
Neuralstem Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 25, 2026, 7:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols

NCT00968084
View directory record Official record
Conditions
Inflammatory Disease, Autoimmune Disease, Immunologic Disease, Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years and older
Enrollment
587 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 25, 2026, 7:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Measurement of Glucose Metabolism in Humans: Effect of Recurrent Hypoglycemia on Hypothalamic GABA

NCT02829593
View directory record Official record
Conditions
Type 1 Diabetes, Healthy
Interventions
hypoglycemia (low blood sugar) and MRI
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 25, 2026, 7:23 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure

NCT01251406
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Placebo, rhNRG-1 Dose 1, rhNRG-1 Dose 2
Drug
Lead sponsor
Zensun Sci. & Tech. Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • Tustin, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 25, 2026, 7:23 PM EDT
Active, not recruiting Phase 2 Interventional

Renal Mechanism of SGLT2 Inhibition

NCT05507892
View directory record Official record
Conditions
Type 2 Diabetes, Diabetic Kidney Disease
Interventions
canagliflozin, Aminohippurate Sodium Inj 20%
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 25, 2026, 7:23 PM EDT
Completed Not applicable Interventional

Digital Mental Health Intervention for Nonsuicidal Self-Injury in Young Adults

NCT05325944
View directory record Official record
Conditions
Nonsuicidal Self Injury, Suicidal Ideation, Depression, Anxiety
Interventions
Self-guided digital intervention for NSSI, Digital intervention for NSSI with coaching, Active control
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 24 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 25, 2026, 7:23 PM EDT
Completed Not applicable Interventional

Organizational Skills Interventions for Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01176136
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Homework, Organization, and Planning Skills (HOPS) Intervention
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 15 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 25, 2026, 7:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Investigating the Cognitive Processes That Underlie Social Knowledge and Behavior

NCT00061334
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

NCT00003199
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
tamoxifen citrate, busulfan, thiotepa, melphalan, aldesleukin, sargramostim, peripheral blood stem cell transplantation, radiation therapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 25, 2026, 7:23 PM EDT
Terminated No phase listed Observational

Ventriculostomy in Subarachnoid Hemorrhage (SAH): Intracranial Pressure (ICP) Open or Not?

NCT01169454
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 25, 2026, 7:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)

NCT00194649
View directory record Official record
Conditions
Contraception
Interventions
Miglustat (Zavesca)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2008 · Synced Oct 25, 2026, 7:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038
View directory record Official record
Conditions
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin Lymphoma
Interventions
Surovatamig, Prednisone (or equivalent), Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Acalabrutinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Boston, Massachusetts • Hackensack, New Jersey • New Brunswick, New Jersey + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 25, 2026, 7:23 PM EDT